Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod

by Zacks Equity Research

The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.

    Why is Alexion (ALXN) Down 3.5% Since its Last Earnings Report?

    by Zacks Equity Research

    Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Achillion (ACHN) Posts Wider-Than-Expected Q1 Loss, Names CEO

      by Zacks Equity Research

      Achillion Pharmaceuticals (ACHN) disappoints with wider-than-expected loss in the first quarter. Appoints Joseph Truitt as new CEO.

        Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1

        by Zacks Equity Research

        The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.

          Strength Seen in Alexion Pharmaceuticals (ALXN): Stock Soars 14.5%

          by Zacks Equity Research

          Alexion (ALXN) was a big mover last session, as the company saw its shares rise more than 14% on the day amid huge volumes.

            Alexion's (ALXN) Earnings Beat Estimates in Q1, Guidance Up

            by Zacks Equity Research

            Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.

              Alexion (ALXN) Tops Q1 Earnings and Sales Beat Estimates

              by Zacks Equity Research

              Alexion surpassed earnings and revenue expectations in the first quarter of 2018.

                What's in the Cards for BioMarin (BMRN) in Q1 Earnings?

                by Zacks Equity Research

                BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales. On the call, management is likely to comment on the launch preparation for pegvaliase.

                  Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season

                  by Zacks Equity Research

                  Alexion Pharmaceuticals (ALXN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                    Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                    by Zacks Equity Research

                    Impressive sales of Alexion's blockbuster drug, Soliris might lead the company toward an earnings beat in Q1.

                      Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?

                      by Zacks Equity Research

                      Alexion Pharmaceuticals, Inc. (ALXN) Sees Hammer Chart Pattern: Time to Buy?

                        Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?

                        by Zacks Equity Research

                        While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.

                          What's in Store for Biogen (BIIB) This Earnings Season?

                          by Zacks Equity Research

                          On the Q1 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.

                            Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics

                            by Zacks Equity Research

                            The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.

                              Indrajit Bandyopadhyay headshot

                              Pharma M&A Active This Week: 4 Potential Buyout Targets

                              by Indrajit Bandyopadhyay

                              Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.

                                Alexion (ALXN) to Acquire Wilson Therapeutics for $855M

                                by Zacks Equity Research

                                Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.

                                  Biotech Stock RoundUp: ALXN & ARNA Up on Study Data, PRTA Teams Up With Celgene

                                  by Zacks Equity Research

                                  The biotech sector was in focus last week with Alexion gaining on positive data on PNH candidate, Arena surges on ulcerative drug data, Solid Biosciences' stock suffering a crash and Prothena teaming up with Celgene.

                                    Alexion (ALXN) Gains On Positive Date From Lead Candidate

                                    by Zacks Equity Research

                                    Alexion's (ALXN) shares gained 3.4% following positive results from a phase III study on its important candidate, ALXN1210, wherein it was compared to its lead drug Soliris.

                                      Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost

                                      by Zacks Equity Research

                                      Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.

                                        The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi

                                        by Zacks Equity Research

                                        The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi

                                          3 ETFs to Watch on Biotech Earnings

                                          by Zacks Equity Research

                                          Major Biotech companies report mixed Q4 results.

                                            Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4

                                            by Zacks Equity Research

                                            Alexion (ALXN) surpass earnings and sales estimates in the fourth quarter of 2017. The company received FDA approval for label expansion of Soliris in the United States.

                                              Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates

                                              by Zacks Equity Research

                                              Alexion surpassed earnings and sales expectations in the fourth quarter of 2017.

                                                REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?

                                                by Zacks Equity Research

                                                Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.

                                                  Why Earnings Season Could Be Great for Alexion Pharmaceuticals (ALXN)

                                                  by Zacks Equity Research

                                                  Alexion Pharmaceuticals (ALXN) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.